Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.41 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.38 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.35 |
| ▸ | SCN10A known ✓ | Q9Y5Y9 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30928945 | 1.00 | CASP3 (0.42) | CASP3SENP8SENP7SENP6KDM1A | |
| SCHEMBL31051602 | 0.98 | — | — | |
| SCHEMBL669824 | 0.98 | — | — | |
| O-Xylene SCHEMBL28789820 | 0.86 | CASP3 (0.41) | CASP3SENP8SENP7SENP6KDM1A | |
| SCHEMBL8108072 | 0.80 | MAPT (0.42) | KDM1AMAOBLMNAL3MBTL1 | |
| Hydrochloric Acid SCHEMBL5008501 | 0.80 | DPP4 (0.53) | CASP3SENP8SENP7SENP6KDM1A | |
| Hydrochloric Acid SCHEMBL3294123 | 0.80 | DPP4 (0.53) | CASP3SENP8SENP7SENP6KDM1A | |
| SCHEMBL23852687 | 0.77 | — | — | |
| SCHEMBL3381094 | 0.77 | — | — | |
| SCHEMBL7216879 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492180-B2 | Process and intermediates for the preparation of Voxelotor | CURIA SPAIN, S.A.U. (ES) | 2025-12-09 | — | — | US | disclosed |
| US-12258355-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| CN-113365992-B | Process and intermediates for the preparation of Wo Sailuo torr | 晶体制药独资有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-116655618-A | Probes for imaging huntingtin | CHDI基金会股份有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20230212190-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2023-07-06 | — | — | US | disclosed |
| CN-107108534-B | Probes for imaging huntingtin | CHDI基金会股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-4006016-A2 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI Foundation, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| US-20220073493-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF VOXELOTOR | CURIA SPAIN, S.A.U. (ES) | 2022-03-10 | — | — | US | disclosed |
| US-20220056008-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF VOXELOTOR | CRYSTAL PHARMA, S.A.U. (ES) | 2022-02-24 | — | — | US | disclosed |
| EP-3898618-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF VOXELOTOR | Crystal Pharma, S.A.U. (ES) | 2021-10-27 | — | — | EP | disclosed |
| US-20030191153-A1 | Antithrombotic amides | ARGENTUM PHARMACEUTICALS LLC | 2003-10-09 | — | — | US | disclosed |
| US-6610704-B1 | Inhibit factor Xa | ELI LILLY AND COMPANY | 2003-08-26 | — | — | US | disclosed |
| US-20020198194-A1 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. | 2002-12-26 | — | — | US | disclosed |
| EP-1140881-A1 | ANTITHROMBOTIC AMIDES | ELI LILLY AND COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039111-A1 | ANTITHROMBOTIC AMIDES | ELI LILLY AND COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |
| US-4866066-A | Thiomethylpyridine derivatives and their use for eliciting a bronchosecretolytic or mucolytic response | LUDWIG HEUMANN & CO. GMBH (DE) | 1989-09-12 | — | — | US | disclosed |
| US-4810715-A | BRONCHOSECRETOLYTIC, MUCOLYTIC | LUDWIG HEUMANN & CO. GMBH (DE) | 1989-03-07 | — | — | US | disclosed |
| EP-0093252-B1 | THIOMETHYLPYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | LUDWIG HEUMANN & CO GMBH (DE) | 1988-03-09 | — | — | EP | disclosed |
| EP-0093252-A2 | Thiomethylpyridine derivatives, process for their preparation and medicaments containing them | LUDWIG HEUMANN & CO GMBH (DE) | 1983-11-09 | — | — | EP | disclosed |
| US-4332944-A | Compositions and use | ZOECON CORPORATION (US) | 1982-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212190-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, HSPBP1 | MAOB 3619/4885DPP4 4352/4885SCN2A 720/4885 |
| US-20030191153-A1 | Antithrombotic amides | F11, TFPI, SERPINC1 | MAOB 702/4885DPP4 804/4885SCN2A 1078/4885 |
| US-20020198194-A1 | Quinoline derivatives | NPY2R, NPY1R, NPY4R | MAOB 1279/4885DPP4 210/4885SCN2A 1190/4885 |
| US-20220073493-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF VOXELOTOR | VPS51, KIF15, VAT1 | MAOB 1876/4885DPP4 3866/4885SCN2A 880/4885 |
| US-12258355-B2 | Probes for imaging huntingtin protein | HTT, HYPK, HSPBP1 | MAOB 3619/4885DPP4 4352/4885SCN2A 720/4885 |
| US-20220056008-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF VOXELOTOR | VAT1, VPS51, VMP1 | MAOB 2973/4885DPP4 3093/4885SCN2A 918/4885 |
| US-12492180-B2 | Process and intermediates for the preparation of Voxelotor | VPS51, KIF15, VAT1 | MAOB 1876/4885DPP4 3866/4885SCN2A 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.